

RESULTS OF ANNUAL GENERAL MEETING

Perth, Australia; 15 November 2017: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises that its 2017 Annual General Meeting was held today. All resolutions put to the meeting were passed on a show of hands. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out below.

Resolutions		For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Non-Binding Resolution to adopt Remuneration Report	7,991,940	297,342	81,252	17,979,156
2	Re-election of Professor Lars Lidgren	26,064,545	175,693	82,751	24,200
3	Re-election of Mr Matthew Callahan	26,058,728	175,010	81,751	27,700
4	Ratification of issue of Shares to various sophisticated and professional investors under ASX Listing Rule 7.1.	25,853,525	335,113	81,751	71,100
5	Ratification of issue of Shares to various sophisticated and professional investors under ASX Listing Rule 7.1A.	25,534,737	334,266	81,501	391,034
6	Ratification of issue of options to Argonaut	25,824,065	342,513	108,661	67,700
7	Approval of 10% Placement Facility	25,880,576	294,162	101,751	66,700
8	Adoption of Orthocell Limited Employee Equity Incentive Plan	7,675,363	604,644	81,751	17,989,431

-ENDS



For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director

P: +61 8 9360 2888
E: paulanderson@orthocell.com.au

Investor and Media enquiries

Ben Walsh
WE Buchan

P: + 61 411 520 012
E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.



Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au